In this review, we explore the evolving evidence linking physiological assessment of coronary artery disease with plaque progression and vulnerability. Reducing clinical events including acute coronary syndromes (ACS) remains the ultimate goal for diagnostic tests and we highlight evidence supporting their use as predictors of patients at risk of adverse clinical events. Historical and contemporary studies support synergy between lesion severity, ischemia, plaque vulnerability and patient prognosis. Ischemia contributes to clinical events through association with plaque burden, however we review the emerging concept that it signifies disturbed lesion hemodynamics with a role in atherothrombosis. Biomechanical pathophysiological forces including endothelial shear stress -the frictional force generated by blood flow on the vessel wall -are increasingly linked with atherogenesis, vulnerable plaque morphology in addition to platelet and leucocyte activation. We conclude by transitioning from the model of the vulnerable plaque to the concept of the 'vulnerable patient' looking more broadly at physiological contributors to Virchow's triad underpinning ACS.
Introduction
The fractional flow reserve (FFR) reflects the extent to which maximal myocardial flow is decreased due to the presence of an epicardial narrowing. (1, 2) Revascularization decisions based on FFR improve prognosis in patients with coronary artery disease. (3, 4) Moving beyond flow-limitation, the anatomical and physiological characteristics of a plaque implicate a role for physiological factors and biomechanical forces in the pathophysiology of plaque rupture. (5) Endothelial shear stress -the frictional force generated by blood flow on the vessel wall -is increasingly linked with atherogenesis and plaque vulnerability in addition to platelet and leucocyte activation. (6, 7) While coronary physiologic indices such as FFR have been proposed for interrogation of the ischemic potential of stable coronary stenoses, lesion hemodynamics are associated with atherosclerotic plaque biology and vulnerability. (8) Coronary physiologic data may be integrated with anatomical information from coronary angiography and intravascular imaging to provide novel insights into lesion pathobiology with potential to better inform the treatment of coronary disease. In this review, we will explore the evolving evidence linking physiological assessment of coronary artery disease with plaque progression and vulnerability. 5 
-Ischemia based on anatomic evaluation (invasive coronary angiography)

Coronary angiography for detecting plaque and assessing vulnerability
Luminal changes demonstrable on coronary angiography have traditionally been used to determine whether a coronary stenosis is of hemodynamic significance i.e. associated with myocardial ischemia. However, x-ray angiography is merely a 'luminogram' and estimating physiological significance from diameter stenosis (DS) is fraught with many pitfalls: the ratio of the minimum luminal diameter to the adjacent normal segment ignores the facts that atherosclerosis is a diffuse disease and angiography alone is often unable to distinguish between normal and diseased segments. The relationship between lesion severity and vulnerability Only a minority of early atherosclerotic plaques progress to high-risk thin-cap fibroatheroma (TCFA) which are thought to be the most common precursors to ruptured plaques.(12) Non-obstructive plaques are more prevalent than obstructive plaques, however the absolute risk of plaque rupture is higher with an obstructive lesion. (8, 13) Contemporary angiographic studies support that at the 6 time of myocardial infarction the underlying lesion on angiography is usually severely stenotic (Mean DS 66+/-12%). (14) Post mortem data confirms the majority of lesions causing fatal infarction are obstructive when plaque burden is analyzed by histopathological cross-sectional area: more than 75% stenosis is seen in 70% of plaque ruptures. (15) It is likely that rapid, though usually asymptomatic progression and resultant stenosis/thrombosis occurs in the days-to-weeks preceding AMI such that acute total vessel occlusion typically develops at the site of an obstructive narrowing.
Studies of non-invasive angiography using CCTA strongly support that the larger plaque size associates with lesion vulnerability. (16) Other high risk atherosclerotic plaque features on CCTA include positive vessel remodeling, lowattenuation plaques, 'napkin-ring' sign, and spotty calcification (17, 18) .
The PROSPECT study of the natural history of atherosclerosis using intravascular ultrasound (IVUS) is the single most important contemporary evidence and supports the notion that events are linked with lesion severity.
Plaque burden ≥70% was the strongest predictor of future events (hazard ratio Analysis of non-culprit lesions in PROSPECT that were responsible for future MACE showed that the majority of these plaques were non-obstructive on 7 baseline angiography (mean diameter stenosis (DS), 32.3±20.6%), but later at the subsequent event the angiographic severity in this subgroup had progressed to a mean DS of 65%. Importantly, the dominant driver of these events was progression of angina; the more robust clinical end-point of AMI in a non-culprit vessel occurred in less than 1% of patients. Taken together, the most likely model of vulnerable plaques is that of step-wise accelerated progression with subclinical plaque ruptures and increasing lumen encroachment, with a continuum of both obstructive and non-obstructive plaques underlying ACS. (19) 
-Ischemia based on functional evaluation
The adverse prognostic impact of ischemia has been well established using 'ischemic threshold' whereby a burden of 1.5 ischemic segments was independently associated with nearly 9-fold increased risk of cardiac death, MI, or late coronary revascularization during a mean follow-up of 2.5 years. (24) Importantly, even when left ventricular function and myocardial scar burden were accounted for, this 'ischemic threshold' remained the strongest independent predictor of 'hard' clinical end-points -cardiac death and MI.
Ischemia may be a surrogate marker for anatomical plaque burden -indeed the COURAGE trial highlighted the intuitive interaction between ischemia on SPECT and anatomical disease burden on baseline angiography (p=0.03). Taken together, the COURAGE data showed anatomic disease burden to be a more consistent predictor of events compared with ischemia. (25), (26) Importantly, this study overlooked the fact that the degree of ischemia was determined before treatment. The influence of ischemia on outcome should be at least partly annulled following initiation of treatments aimed at alleviating its existence -thus it is unsurprising that plaque burden was more predictive of events. The COURAGE nuclear substudy did not show that ischemia was associated with risk of future events, however it was not powered to perform this non prespecified analysis and may have been affected by selection bias. (27) Other contemporary cohorts have found ischemia on SPECT to be the strongest predictor of events, providing complementary additional information to the anatomical disease burden assessed by coronary artery calcium score. (28) Amongst patients with previous revascularization, the residual ischemic burden is the strongest independent predictor of future events, consistently identifying highrisk patients in groups with similar degrees of anatomical plaque burden. (29, 30) 
Lessons from FAME -is FFR a predictor of lesion vulnerability?
The FAME-II study (FFR versus Angiography for Multivessel Evaluation II)
showed that patients with functionally significant lesions (FFR≤0.80) had superior outcomes with PCI and optimal medical therapy compared with optimal medical therapy alone.(3) Critics argue that urgent revascularizations were to be expected in this trial given that both patients and physicians were potentially aware of the significant lesions that were not stented. This may have lowered the threshold for urgent revascularization in patients with FFR-positive stenosis in the medical therapy group. Besides the fact that this phenomenon did not happen in the registry patients (also aware of the presence of untreated lesions), half of the urgent revascularizations occurred in the context of positive biomarkers or new ECG changes, while 80% occurred in patients with these findings or rest angina. A blinded and independent clinical event committee adjudicated all these events. In addition, it is very likely that the large number of unplanned revascularizations in patients randomized to medical therapy actually limited the number of "hard end-points" (death or myocardial infarctions). The two-year follow up data showed that after excluding the potentially more benign periprocedural myocardial infarctions, the incidence of death or myocardial infarction was lower in the PCI group than in the medical-therapy group (4.6% vs. 8.0%, p=0.04).(3) There was a significantly lower incidence of revascularization procedures triggered by ECG changes or MI in the PCI group than in the medical-therapy group (3.4% versus 7.0%, p=0.01).
Equally, FAME and now 15-year follow-up data from the DEFER study These findings are consistent with the hypothesis that FFR assists in the prediction of plaque behaviour: the ischemic potential of a lesion may be a surrogate marker of plaque vulnerability with its attendant risk of rupture. It is important to note that a lower absolute value of FFR corresponds with a higher risk of events, however risk stratification using this approach does not necessarily detect which ischemia producing lesion will drive events. Prospective studies have shown that up to half of future MACE relates to non-target vessels, but a large proportion of the future MACE is attributable to the lesion's FFR. Stenting these hemodynamically significant vulnerable lesions may prevent future coronary events.(33)
How ischemia affects plaque vulnerability and propensity to ACS
There are two main reasons for why an ischemia-producing lesion is more likely to cause ACS than a non-ischemia-producing lesion. 
